Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Apr 26, 2013 5:00pm

166 Views

Post# 21307623

RE: RE: price to watch.

So clearly no announcment from RVX about the record date yesterday or today. From what I understand (and Geric implied in the previous post) is that RVX needs to release a statement 4 weeks prior to the meeting date. The meeting date can still be May 28th, as long as they announce the record date by Monday April 29th or Tuesday April 30th, right? Or does RVX need to announce the record data at least 3 days ahead to allow for shares bought on announcement day to settle. Anyone have a clue?

Bullboard Posts

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024